42 / 62
Pujol J, et al. Ann Oncol 2018;29(suppl 5):Abstr 1664O
HR (adjusted) atezolizumab group = 2.26 (95%CI 1.30, 3.93); p=0.004
Time, months
0 1 2 3
5 6 7 8 9
4
Median follow-up: 13.7 months (95%CI 12.7, NR)
Chemotherapy (n=24): 4.3 (1.5, 5.9); 21 events, 3 censored
Atezolizumab (n=49): 1.4 (1.2, 1.5); 46 events, 3 censored
6-month PFS rate for atezolizumab group: 6.3% [0.0, 13.1]
Progression-free survival
1.0
0.8
0.6
0.4
0.2
0
Median PFS, months (95%CI)
PFS (ITT population)